As readers might remember, our THIRDSPACE patent knowledgebase project is intended to provide the user with access to scientific and intellectual property information. We presented our two posters on the REDWING eye medicine module at the World Ophthalmology Congress in Berlin in early June — a huge event with thousands of eyecare specialists from every corner of the world in attendance. Interest in our work was considerable. Unfortunately, there was an error in the abstract book, which contains a fragment from somebody else’s abstract where our two submitted abstracts were supposed to go. (Other participants suffered from this error too.) On the brighter side, the free abstract CD (sponsored by MSD Ophthalmics) had the correct abstracts.
Our consulting business continues to accelerate. Small and/or virtual companies (our strongest customer segment) are clearly gaining confidence, and many have regained access to venture capital or other funding that had all but dried up during 2009. Most notably, analysts from VCs who are interested in obtaining our rapid-response opinion on European perspectives for late-stage or newly approved drugs also show increased interest in our assessments. We are cooperating with the Coleman Research Group which arranges these quick assignments for us.
A few days ago, the Cambridge Healthtech Institute’s Insight Pharma Reports division launched our newest public technology and and market assessment, Drug Repositioning: Extracting Added Value from Prior R&D Investments. You can find the summary and the report brochure here.
This summer will be a decisive time in many respects, so please stay tuned for our updates.